G
G. Kurteva
Publications - 13
Citations - 1108
G. Kurteva is an academic researcher. The author has contributed to research in topics: Capecitabine & FOLFOX. The author has an hindex of 8, co-authored 13 publications receiving 981 citations.
Papers
More filters
Journal ArticleDOI
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Florian Lordick,Yoon-Koo Kang,Hyun Cheol Chung,Pamela Salman,Sang Cheul Oh,György Bodoky,G. Kurteva,Constantin Volovat,Vladimir Moiseyenko,Vera Gorbunova,Joon Oh Park,Akira Sawaki,Ilhan Celik,Heiko Götte,Helena Melezínková,Markus Moehler +15 more
TL;DR: Addition of cetuximab to capecitabine-cisplatin provided no additional benefit to chemotherapy alone in the first-line treatment of advanced gastric cancer in the EXPAND trial.
Journal ArticleDOI
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
Paulo M. Hoff,Andreas Hochhaus,Bernhard C. Pestalozzi,Niall C. Tebbutt,Jin Li,Tae Won Kim,Krassimir D. Koynov,G. Kurteva,Tamás Pintér,Ying Cheng,Brigitte M. Van Eyll,Laura Pike,Anitra Fielding,Jane Robertson,Mark P Saunders +14 more
TL;DR: Because of the lack of improvement in OS, cediranib plus an oxaliplatin-based regimen cannot be recommended as a treatment for patients with previously untreated metastatic colorectal cancer.
Journal ArticleDOI
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Stephen R. D. Johnston,Roberto Hegg,Seock-Ah Im,In Hae Park,Olga Burdaeva,G. Kurteva,Michael F. Press,Sergei Tjulandin,Hiroji Iwata,Sergio Daniel Simon,Sarah Kenny,Severine Sarp,Miguel Izquierdo,L. S. Williams,William J. Gradishar +14 more
TL;DR: The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy.
Journal ArticleDOI
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
Robert J. Motzer,Anna Alyasova,Dingwei Ye,Andrey Karpenko,Hanzhong Li,Boris Alekseev,Liping Xie,G. Kurteva,Ruben Dario Kowalyszyn,Oleg Karyakin,Y. Neron,Thomas Cosgriff,Laura C. Collins,Thomas Brechenmacher,Chinjune Lin,L. Morgan,Lin Yang +16 more
TL;DR: These results confirm the PFS benefit of second-line everolimus after first-line sunitinib or other anti-VEGF therapies and the safety profile ofEverolimus was consistent with previous experience.
Journal ArticleDOI
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.
Florian Lordick,Yoon-Koo Kang,Pamela Salman,Sang Cheul Oh,György Bodoky,G. Kurteva,Constantin Volovat,Vladimir Moiseyenko,Akira Sawaki,Joon Oh Park,Vera Gorbunova,Heiko Goette,Helena Melezínková,Christopher Stroh,Markus Moehler +14 more
TL;DR: This analysis assessed treatment outcome according to tumor HER2 status (a pre-defined subgroup) and EGFR expression in EXPAND study pts, finding that pts with HER2 +ve tumors had a longer median overall survival.